Three Month Follow-Up of Patients With COVID-19 Pneumonia Complicated by Pulmonary Embolism

Cecilia Calabrese1*, Anna Annunziata2, Martina Flora2, Domenica Francesca Mariniello1, Valentino Allocca1, Maria Ilaria Palma1, Antonietta Coppola2, Ilenando Meoli2, Pia Clara Pafundi3 and Giuseppe Fiorentino2

1Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, Naples, Italy, 2Department of Intensive Care, A.O.R.N dei Colli, Naples, Italy, 3GEMELLI GENERATOR - Facility of Epidemiology and Biostatistics, Fondazione Poloclinico Gemelli, Roma, Italy

Background: Previous studies have demonstrated persistent dyspnoea and impairment of respiratory function in the follow-up of patients who have recovered from COVID-19 pneumonia. However, no studies have evaluated the clinical and functional consequences of COVID-19 pneumonia complicated by pulmonary embolism.

Objective: The aim of our study was to assess the pulmonary function and exercise capacity in COVID-19 patients 3 months after recovery from pneumonia, either complicated or not by pulmonary embolism.

Methods: This was a retrospective, single-centre, observational study involving 68 adult COVID-19 patients with a positive/negative clinical history of pulmonary embolism (PE) as a complication of COVID-19 pneumonia. Three months after recovery all patients underwent spirometry, diffusion capacity of the lungs for carbon monoxide (DLCO), and 6 minute walk test (6MWT). In addition, high-resolution computed tomography (HRCT) of the lung was carried out and CT-pulmonary angiography was conducted only in the PE+ subgroup. Patients with a previous diagnosis of PE or chronic lung diseases were excluded from the study.

Results: Of the 68 patients included in the study, 24 had previous PE (PE+) and 44 did not (PE−). In comparison with the PE− subgroup, PE+ patients displayed a FVC% predicted significantly lower (87.71 ± 15.40 vs 98.7 ± 16.7, p = 0.009) and a significantly lower DLCO% predicted (p = 0.023). In addition, a higher percentage of patients were dyspnoeic on exercise, as documented by a mMRC score ≥ 1 (75% vs 54.3%, p < 0.001) and displayed a SpO2 <90% during 6MWT (37.5% vs 0%, p < 0.001). HRCT features suggestive of COVID-19 pneumonia resolution phase were present in both PE+ and PE− subjects without any significant difference (p = 0.24) and abnormalities at CT pulmonary angiography were detected in 57% of the PE+ subgroup.

Conclusion: At the 3 month follow-up, the patients who recovered from COVID-19 pneumonia complicated by PE showed more dyspnoea and higher impairment of pulmonary function tests compared with those without PE.

Keywords: COVID-19, pulmonary embolism, lung function, spirometry, DLCO, KCO, six minute walk test
INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by the novel Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2), can involve multiple organs, though the lungs’ involvement plays the key role in all the most severe clinical manifestations. After SARS-CoV-2 accesses human cells by the angiotensin-converting enzyme 2 (ACE2) receptors, mostly expressed by type 2 pneumocytes, an acute systemic inflammatory response may occur, followed by several lung pathological events (Mo et al., 2020). The extensive injury of alveolar epithelial cells and endothelial cells can elicit a fibroproliferative response. Chronic alveolar and vascular remodeling can also, in turn, evolve either in lung fibrosis and/or pulmonary hypertension (Frija-Masson et al., 2020; Venkataraman and Frieman, 2017). In addition, the interplay between inflammation and thrombosis, known as thrombo-inflammation, may contribute to a procoagulant state, which can be responsible for the vascular thrombosis frequently detected in small caliber pulmonary vessels (Bikdeli et al., 2020; Goeijenbier et al., 2012; Klok et al., 2020). Venous thromboembolism has been reported particularly in severe COVID 19 patients, with a prevalence ranging from 17 to 69%, and genetic risk factors seem to play a pathogenetic role (Calabrese et al., 2021). While the clinical manifestations of patients affected by COVID-19 pneumonia con

MATERIALS AND METHODS
We conducted a retrospective, single-centre, observational study involving adult patients who received a diagnosis of SARS-CoV-2 pneumonia confirmed by real time reverse transcription polymerase chain reaction (RT-PCR) on naso-pharyngeal swab and high resolution computed tomography (HRCT) of the lung. All enrolled patients had either severe COVID-19 pneumonia (in the presence of fever, cough, dyspnea, fast breathing, one among respiratory rate >30 breaths/min, severe respiratory distress, or SpO2 <90% on room air) or critical with mild ARDS (P/F between 200 and 300 mmHg, with either PEEP or cPAP ≥ 5 cm H2O) (SARI Guidelines, 2019).

Patients included in the study were divided into two subgroups based on the positive/negative clinical history of pulmonary embolism (PE) as a complication of COVID-19 pneumonia, i.e. PE+ and PE−, respectively. PE diagnosis was confirmed by CT pulmonary angiography. All patients were treated with the best of care according to the NIH COVID 19 guidelines (NIH Covid-19 Guidelines, 2019), including prophylactic dose anticoagulation unless contraindicated. Patients with COVID-19 who experienced an incident thromboembolic event were managed with therapeutic doses of anticoagulant therapy. After discharge, PE+ patients were treated with direct oral anticoagulants (DOACs) for at least 6 months. Following hospital discharge till follow-up visit, all patients did not need any clinical visits or hospital admission. Three months after recovery from SARS-CoV-2 infection, all patients performed pulmonary function tests at the outpatient service of the Department of Respiratory Pathophysiology, Monaldi Hospital, Naples (Italy), including spirometry, DLCO, and 6MWT. In addition, HRCT of the lung was carried out and CT pulmonary angiography was performed only in the PE + subgroup.

Based on the clinical data collected from medical records about all clinical comorbidities and ongoing therapies, confirmed by lung HRCT, we excluded from the study all patients with a previous diagnosis of chronic lung diseases (i.e., chronic obstructive pulmonary disease, bronchial asthma, diffuse parenchymal lung disease) or PE.

All subjects provided written informed consent to participate in the study, which was approved by the local ethics committee of the University of Campania Luigi Vanvitelli and A.O.R.N. Ospedali dei Colli, in accordance with the 1976 Declaration of Helsinki and its later amendments (AOC-0020053-2020).

Data Collection
Baseline demographic and anthropometric characteristics (sex, age and body mass index), history of smoking, and comorbidities were collected from clinical medical records.

Spirometry and single-breath DLCO test were performed according to the American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines (Graham et al., 2017, 2019), using Vyntus BODY (Vyaire Medical).

The following spirometric parameters were measured: forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and forced expiratory flow at 25, 50, 75% of the forced vital capacity (FEF 25, FEF 50 and FEF 75, respectively). DLCO, alveolar volume (VA), and transfer coefficient of the lung for carbon monoxide (KCO) were measured by the single-breath DLCO test.

All parameters were expressed as absolute values and percentages of the predicted value (%) and considered reduced if below the lower limit of normality (LLN), according to the
An obstructive ventilatory defect was defined by a FEV1/FVC ratio lower than LLN. A flow-volume curve displaying an FVC % < 80% and an FEV1/FVC ≥ 70% was considered suggestive of a restrictive ventilatory defect (Soriani et al., 2012). Reduced DLCO % and KCO % were defined as lower than 80% of the predicted value, according to the Global Lung Function Initiative 2017 reference equations for DLCO (Stanojevic et al., 2017).

Proper performance of spirometry and single-breath DLCO test was ensured by medical personnel and all the measures suggested by local national guidelines to avoid the risk of SARS-CoV2 infection were adopted (Tognella and Piccioni, 2021). In particular, the measurement of lung volumes by plethysmography, due to the objective difficulties in the disinfection of the chamber in the post-pandemic phase 2, was not allowed. All enrolled patients had to exhibit a negative nasopharyngeal swab for the molecular detection of SARS-CoV-2 RNA before pulmonary functional exams.

The 6 minute walk test (6MWT) was performed according to ATS/ERS guidelines (Holland et al., 2014). The distance walked during 6 minutes was measured and compared with 6MWT predictive values according to the reference equation published by ENRIGHT and SHERRILL (Enright and Sherrill, 1998) and considered reduced if lower than LLN. The dyspnea intensity was assessed by the modified Medical Research Council (mMRC) dyspnea scale (range from 0- dyspnea only with strenuous exercise to 4- too dyspneic to leave the house or breathless when dressing) (Fletcher et al., 1959; Williams, 2017). Finally, the Borg dyspnea scale score (range from 0 – nothing at all to 10 very severe) was assessed before and after 6MWT. During the test, peripheral capillary oxygen saturation (SpO2) was measured by pulse oximetry on the index finger and SpO2 levels below 90% were considered pathological.

Statistical Analysis
All variables included in the study were first analyzed by descriptive statistics techniques. In depth, qualitative variables were expressed as number and percentage, while quantitative variables either median and interquartile range (IQR) or mean and standard deviation (SD), based on their distribution, were assessed by the Shapiro-Wilk test. Between the groups, the differences at baseline were tested either by the parametric paired Student t Test or by the non-parametric Wilcoxon signed rank test, whilst qualitative data were analyzed either by the Chi Square test or the Fisher Exact test. The most significant findings were further exemplified by box-plots and bar diagrams.

A p-value < 0.05 was considered statistically significant. Data were analyzed using SPSS Software, Version 26 (IBM, Armonk, New York, United States), and STATA 16 software (StataCorp. 2019: StataCorp LP, College Station, TX, United States).

RESULTS
In total, 68 COVID-19 patients were enrolled in the study, 24 with PE (PE+) and 44 without (PE−). All baseline clinical and functional characteristics of the whole study population are described in Table 1. The mean age was 54.9 (± 12.8) years and the majority of patients were males (73.5%), nonsmokers (61.8%), and overweight (median BMI 28). The most frequent comorbidities were systemic arterial hypertension (45.6%) and obesity (41.2%) and 39 (57.4%) patients showed more than one comorbidity. The median time from the recovery from SARS-CoV-2 infection to the clinical follow-up visit was 90 days (IQR 60–120).

Spirometry and DLCO were uneventfully completed in all subjects. Abnormalities at spirometry were detected in a small percentage of patients (14.7%), with 4 (5.9%) showing an obstructive ventilatory defect and 6 (8.8%) displaying a flow-volume curve suggestive of a restrictive ventilatory defect. A reduction of DLCO < 80% predicted was instead observed in 27 (39.7%) patients and 7 (10.3%) showed a concomitant reduction of KCO < 80%, while 20 (29.4%) had a normal KCO.

The 6MWT was performed in all study population. Most patients (37, 54.4%) complained of dyspnea, assessed by an mMRC grade ≥ 1. Moreover, 13.2% of patients displayed a SpO2 < 90% during the test, and 25% had a distance walked below the LLN. All patients, except for three, complained of increased dyspnea after the test, as rated by the Borg dyspnea scale.

Altogether, 57 of the 68 patients performed HRCT of the lung. Radiological changes suggestive of a resolution phase of COVID-19 pneumonia, represented by residual areas of ground glass opacity (GGO) and/or consolidations and/or linear bands, were present in 78.9% of patients.

The comparison of PE+ and PE− subgroups did not disclose any significant difference for sex and comorbidities. PE+ patients, indeed, were significantly older than PE− patients (61 ± 11.1 vs 51.5 ± 12.5, p = 0.003) and also had a higher prevalence of smoking habits (p = 0.015) (Table 2). In addition, we did not observe any significant difference between PE+ and PE− subgroups in the prevalence of patients with severe or critical with mild ARDS COVID-19 pneumonia (8 vs 15% and 92 vs 85%, p = 0.476, respectively).

The results of the pulmonary functional tests in the two subgroups of patients are described in Table 2. At the spirometry, PE+ patients displayed a FVC% predicted significantly lower than PE− (87.71 ± 15.40 vs 98.7 ± 16.7, p = 0.009). In particular, a higher percentage of PE+ patients had a FVC% < 80% in comparison with PE− (29.1 vs 6.8%, p = 0.033) (Figure 1, left panel). Moreover, the flow volume curve suggestive of a restrictive ventilator defect was more prevalent in PE+ compared to PE− subgroup, although without reaching a statistical significance (16.7% vs 4.5%, p = 0.212). PE+ patients also showed a significantly lower DLCO % predicted (p = 0.023) (Figure 1, right panel). Instead, no statistical difference in KCO% was observed between PE+ and PE−, though a higher percentage of PE+ patients had a concomitant reduction of DLCO% and KCO%.

The main symptom complained by all COVID-19 survivors was persistent dyspnea, which was significantly more prevalent in PE+ as compared to PE− subgroup, as demonstrated by the
TABLE 1 | Baseline characteristics of the study population (n = 68).

| Age (yrs) (mean ± SD) | 54.9 (12.8) |
|-----------------------|-------------|
| Sex (M/F), n (%)     | 50 (73.5)/ 18 (26.5) |
| BMI, median [IQR]    | 28 [25–31] |
| Smoking habit, n (%) | 2 (2.9) |
| Yes                   | 42 (61.8) |
| No                    | 24 (35.3) |
| Comorbidities, n (%) | 31 (45.6) |
| Arterial hypertension| 5 (7.4) |
| Cardiomyopathy        | 10 (14.7) |
| Diabetes Mellitus     | 28 (41.2) |
| Obesity               | 15 (22.1) |
| SpO2 (%)              | 80% |
| mMRC dyspnea score ≥1 | (75% vs 54.3%, p < 0.001) |
| FEV1 (% mean ± SD)    | 94.5 (17.9) |
| FVC (% mean ± SD)     | 94.8 (17) |
| DLCO % < 80, n (%)    | 27 (39.7) |
| KCO % (mean ± SD)     | 99.9 (19.2) |
| KCO% < 80%, n (%)     | 8 (11.8) |
| DLCO % < 80% + KCO <80%, n (%) | 20 (29.4) |
| 6MWT                   | 90 (60–120) |
| mMRC ≥1, n (%)        | 37 (54.4) |
| SpO2 <90% 6MWT, n (%) | 9 (13.2) |
| Walk distance<LLN, n (%) | 17 (25) |
| Lung HRCT, n (%)      | 6 (9.1) |
| Normal                | 45 (66.3) |
| Not performed         | 11 (16.1) |
| Interval discharge and respiratory function test (days), median (IQR) | 90 (60–120) |

DISCUSSION

The main objective of the present study was to assess potential differences in pulmonary functional impairment in COVID-19 survivors with pneumonia either complicated or not by PE. At the 3 month follow-up, COVID-19 survivors with previous PE showed a significantly lower FVC% and DLCO%. Although a higher percentage of PE+ patients had a concomitant reduction of DLCO% and KCO%, the difference between the two subgroups did not reach statistical significance. Recently, several authors have discussed the clinical significance of the reduction of DLCO and whether it is associated with a decrease in KCO among COVID-19 survivors.

DLCO represents the lung’s ability to exchange gas and may occur with various combinations of KCO and VA, each suggesting different underlying pathological modifications. KCO, the transfer coefficient of the lung for carbon monoxide, is a measure of CO uptake from alveolar gas and is affected by the thickness and area of the alveolar-capillary membrane, blood volume, and hemoglobin concentration/properties in capillary vessels supplying ventilated alveoli. A reduced DLCO with either normal or near normal KCO might be related to a reduced alveolar volume caused by changes in the mechanical properties of the chest wall and respiratory muscles. Conversely, when both DLCO and KCO are reduced, we might suspect either membrane or pulmonary capillary abnormalities (Nsair et al., 2020).

Unexpectedly, in the PE+ subgroup, we did not find any significantly higher prevalence of patients showing a reduction of both DLCO % and KCO %, although abnormalities suggestive of pulmonary embolism at CT pulmonary angiography were present after 3 months in this subset of patients. This finding might be due to the relatively small sample size of our study population, with only 10% of them showing functional abnormalities. In addition, Laveneziana et al. (2021) have suggested that reduction of both DLCO and KCO could be in favor of lesions involving alveolar membrane and/or pulmonary capillaries susceptible of some recovery. On the contrary, the reduction of the only DLCO with normal KCO suggests definitive alveolar loss destruction with no perspective of recovery. Of note, in the majority of both PE+ and PE− subjects the two functional parameters were within the normal ranges, whilst about one-third displayed a reduction of only DLCO with normal KCO. Similarly, Mo X and colleagues, who evaluated at the discharge 110 COVID-19 survivors classified into three groups of severity, observed a higher reduction of both DLCO and total lung capacity in the most severe cases. In about half of patients with reduced DLCO, KCO remained within the normal ranges (Mo et al., 2020).

The most frequently observed ventilatory deficit, though in a small percentage of patients, was the restrictive, with a higher percentage of PE+ patients displaying a reduced forced vital capacity. However, a restrictive ventilatory deficit might be associated with the condition of obesity, which was frequently observed in COVID-19 patients and documented in the present study in more than 40% of both PE+ and PE− patients. Moreover, it is of note that the majority of COVID-19 pneumonia survivors did not have any clinically significant changes in spirometry at 3 month follow-up.

Regarding the exercise test, indeed, we observed a significantly higher prevalence of PE+ patients complaining of dyspnea on
TABLE 2  | Comparison of baseline characteristics between PE+ and PE− subgroups.

|                          | PE+ (n = 24) | PE− (n = 44) | p     |
|--------------------------|-------------|-------------|-------|
| Age (yrs) (mean ± SD)    | 61 (11.1)   | 51.5 (12.5) | 0.003 |
| Sex (M/F, n (%))         | 19(79.2)/5(20.8) | 31(70.5)/13(29.5) | 0.436 |
| BMI, median [IQR]        | 28.5 [26–32.5] | 27.5 [25–31] | 0.624 |
| Smoking habit, n (%)     | Yes 2 (8.3) | – | 0.015 |
|                          | No 10 (41.7) | 32 (72.7) | |
| Comorbidities, n (%)     | 14 (58.3) | 17 (38.6) | 0.119 |
|                          | 3 (12.5) | 2 (4.5) | 0.475 |
|                          | 6 (25) | 4 (9.1) | 0.158 |
|                          | 10 (41.7) | 18 (40.9) | 0.952 |
| Interpretation of spirometry, n (%) | 20 (83.3) | 38 (86.4) | 0.091 |
|                          | 4 (16.7) | 2 (4.5) | |
|                          | — | 4 (8.1) | |
| Diffusion capacity test  | 79.5 [81–89.5] | 86.5 [73.3–95.5] | 0.023 |
|                          | 12 (50) | 15 (34.1) | 0.200 |
|                          | 95.2 (18.2) | 102.3 (19.4) | 0.160 |
|                          | 4 (16.7) | 4 (9.1) | 0.354 |
|                          | 4 (16.7) | 3 (6.8) | 0.390 |
|                          | 8 (33.3) | 12 (27.3) | 0.600 |
| 6MWT                      | 18 (75) | 19 (64.3) | <0.001 |
|                          | 9 (37.5) | 0 | <0.001 |
|                          | 3 (16.7) | 14 (40) | 0.088 |
|                          | 2 (10) | 10 (27) | 0.244 |
|                          | 18 (90) | 27 (73) | |

SD, standard deviation; M, Male; F, Female; BMI, Body Mass Index; IQR, interquartile range; GERD, Gastroesophageal Reflux Disease; FEV1, Forced expiratory volume in one second; FVC, Forced Vital Capacity; FEF 25, FEF 50 and FEF 75, forced expiratory flow at 25, 50, 75% of the forced vital capacity; DLCO, diffusion capacity of the lungs for carbon monoxide; KCO, transfer coefficient of the lung for carbon monoxide; mMRC, modified Medical Research Council Dyspnea scale; 6MWT, 6-minute walk test; LLN, Lower limit of normality; HRCT, high resolution computed tomography; SpO2, peripheral capillary oxygen saturation.

*We considered only the real number of patients (57) who performed the exam.

FIGURE 1  | Box-plot showing differences between PE+ AND PE− in terms of FVC% <80% (29.1 vs 6.8%, p = 0.033) (on the left) and in terms of DLCO% (79.5 [81–89.5] vs 86.5 [73.3–95.5]; p = 0.023) (on the right). PE, Pulmonary Embolism; FVC, Forced Vital Capacity; DLCO, Diffusion capacity of the lungs for carbon monoxide; LLN, Lower Limit of Normality.
vascular damage induced by SARS-CoV-2. Huang et al. (2021) with chest CT abnormalities, thus leading to the hypothesis of the authors observed that a decreased DLCO was not associated defects and low diffusion patterns. In about one third of patients, in more than 50% of patients with a mix of restrictive ventilatory perfusion defect in 57% of PE+ patients.

Findings from CT pulmonary angiography demonstrated recovery rather than to pulmonary parenchymal alterations. These data suggest that the higher clinical and functional impairment of PE+ patients could be a consequence of a pulmonary perfusion defect persisting 3 months after the recovery rather than to pulmonary parenchymal alterations. Findings from CT pulmonary angiography demonstrated perfusion defect in 57% of PE+ patients.

Frija-Masson et al. (2020) found abnormal lung function tests in more than 50% of patients with a mix of restrictive ventilatory defects and low diffusion patterns. In about one third of patients, the authors observed that a decreased DLCO was not associated with chest CT abnormalities, thus leading to the hypothesis of vascular damage induced by SARS-CoV-2. Huang et al. (2021) further observed no significant correlation between total severity score at chest CT and pulmonary functional parameters during follow-up visits. The authors also observed a reduction of DLCO in more than 50% of patients, with a higher incidence of DLCO impairment associated with a lower percentage of predicted TLC and 6MWD in severe as compared to moderate and mild disease. The authors further observed that a small percentage of patients with no residual abnormalities presented with a slight decrease in DLCO.

Our study is of course characterized by several limitations. First, the relatively small sample size and the short follow-up mean that the results need to be interpreted carefully. As previously stated, the cost of the nasopharyngeal swab for the molecular detection of SARS-CoV-2 RNA, which was needed to perform the pulmonary function tests, limited the number of patients who agreed to the study participation. As for follow-up, we performed further PFTs 18 months after the recovery from SARS-CoV-2 infection in 10 PE+ and PE− patients of the 27 who displayed a reduction of FVC% and/or DLCO at 3 month follow-up. Overall, seven patients saw an improvement of DLCO, which reached normal percentage predicted values in four cases, while the impairment remained stable in three patients. One patient also had a reduction of FVC% predicted value, which returned at normal values at 18-month follow-up (data not published). Based on these findings, we can hypothesize that most patients should experience recovery from functional impairment. Finally, the diagnosis of restrictive pattern exclusively performed on the reduced FVC associated with either a normal or higher FEV1/FVC is questionable. However, the measurement of TLC by plethysmography was avoided due to the restrictions imposed by local national guidelines regarding pulmonary function tests during the COVID-19 pandemic (Tognella and Piccioni, 2021).

These limitations suggest the need for larger study populations and longer follow-up studies to better establish the characteristics and trends of modification of lung function and exercise tolerance in COVID-19 survivors complicated by PE. However, based on our findings, which depict a higher pulmonary functional impairment at 3-month follow-up among patients with a history of pulmonary embolism complicating SARS-CoV2 pneumonia, we suggest using diagnostic exams to assess the presence of pulmonary embolism in COVID-19 survivors with persistent dyspnea, DLCO impairment, and peripheral oxygen desaturation during the 6MWT.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The study was approved by University of Campania “Luigi Vanvitelli” and A.O.R.N Ospedali dei Colli. The patients provided their written informed consent to participate in this study.

---

**FIGURE 2** [Bar diagram showing differences between PE+ AND PE− in terms of mMRC ≥1 (75 vs 64.3%, p < 0.001) (upper panel) and for SpO2 <90% during 6-minute walk test (6MWT) (37.5 vs 0%, p < 0.001) (lower panel), PE, Pulmonary Embolism; mMRC, modified Medical Research Council Dyspnea scale; 6MWT, 6-minute walk test.](image-url)
AUTHOR CONTRIBUTIONS

GF, CC, and AA contributed to conception and design; AC, IM, and MF contributed to experimental procedures; DM, VA, and MP were involved in the acquisition of data; PP was involved in data analysis; PP and CC interpreted the data; CC, PP, and AA drafted the article; GF and CC critically revised the article for important intellectual content; all authors approved the final version to be published.

REFERENCES

Bikdeli, B., Madhavan, M. V., Jimenez, D., Chuich, T., Dreyfus, I., Driggin, E., et al. (2020). COVID-19 and Thrombosis or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. J. Am. Coll. Cardiol. 75 (23), 2950–2973. doi:10.1016/j.jacc.2020.04.031

British Thoracic Society Guidance (2020). British Thoracic Society Guidance on Respiratory Follow up of Patients with a Clinico-Radiological Diagnosis of COVID-19 Pneumonia. Available at: https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19-resp-follow-up-guidance-post-covid-pneumonia/

Cortés-Telles, A., López-Romero, S., Figueroa-Hurtado, E., Pou-Aguilar, Y. N., Wong, A. W., Milne, K. M., et al. (2021). Pulmonary Function and Functional Capacity in COVID-19 Survivors with Persistent Dyspnea. Respir. Physiol. Neurobiol. 288, 103644. doi:10.1016/j.resp.2021.103644

Enright, P. L., and Sherrill, D. L. (1998). Reference Equations for the Six-Minute Walk in Healthy Adults. Am. J. Respir. Crit. Care Med. 158 (5), 1384–1387. doi:10.1164/ajccr.158.5.9710086

Fletcher, C. M., Elmes, P. C., Fairbairn, A. S., and Wood, C. H. (1959). Significance of Respiratory Symptoms and the Diagnosis of Chronic Bronchitis in a Working Population. BMJ 2 (5147), 257–266. doi:10.1136/bmj.2.5147.257

Frija-Masson, J., Debry, M. P., Gilbert, M., Lescure, F. X., Traxert, F., Borie, R., et al. (2020). Functional Characteristics of Patients with SARS-CoV-2 Pneumonia at 30 days post-infection. Eur. Respir. J. 56 (2), 2001754. doi:10.1183/13993003.01754-2020

Goeree, R., van Wissen, M., van de Weeg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C. N., et al. (2012). Review: Viral Infections and Mechanisms of Thrombosis and Bleeding. J. Med. Virol. 84 (10), 1680–1696. doi:10.1002/jmv.23354

Graham, B. L., Brusasco, V., Burgos, F., Cooper, B. G., Jensen, R., Kendrick, A., et al. (2017). 2017 ERS/ATS Standards for Single-Breath Carbon Monoxide Uptake in the Lung. Eur. Respir. J. 49 (1), 1600016. doi:10.1183/13993003.00016-2016

Graham, B. L., Steenbruggen, I., Miller, M. R., Barjaktarevic, I. Z., Cooper, B. G., Hall, G. L., et al. (2019). Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 200 (8), e70–e88. doi:10.1164/ rccm.201908-1590ST

Holland, A. E., Spruit, M. A., Troosters, T., Puhar, M. A., Pepin, V., Saeys, D., et al. (2014). An Official European Respiratory Society/American Thoracic Society Technical Standard: Field Walking Tests in Chronic Respiratory Disease. Eur. Respir. J. 44 (6), 1428–1446. doi:10.1183/09031936.00150314

Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., et al. (2021). 6-Month Consequences of COVID-19 in Patients Discharged from Hospital: A Cohort Study. Lancet 397, 10270. doi:10.1016/S0140-6736(20)32656-8

Klok, F. A., Kruij, M. J. H. A., van der Meer, N. J. M., Arbous, M. S., Gommers, D. A. M. F. J., Kant, K. M., et al. (2020). Incidence of Thrombotic Complications in Critically Ill ICU Patients with COVID-19. Thromb. Res. 191, 145–147. doi:10.1016/j.thromres.2020.04.013

Laveneziana, P., Sesé, L., and Gille, T. (2021). Pathophysiology of Pulmonary Function Anomalies in COVID-19 Survivors. Breathe 17 (3), 210065. doi:10.1183/20734735.0065-2021

Mendez, R., Latorre, A., González-Jiménez, P., Feced, L., Bouzas, L., Yépez, K., et al. (2021). Reduced Diffusion Capacity in COVID-19 Survivors. Prim. Care Respir. J. 36 (6), 2001832. doi:10.1183/13993003.001832-2020

Nusair, S. (2020). Abnormal Carbon Monoxide Diffusion Capacity in COVID-19 Patients at Time of Hospital Discharge. Eur. Respir. J. 56 (1), 2001852. doi:10.1183/13993003.01852-2020

Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., et al. (2012). Multi-ethnic Reference Values for Spirometry for the 3-95-yr Age Range: The Global Lung Function 2012 Equations. Eur. Respir. J. 40 (6), 1324–1343. doi:10.1183/09031936.0080312

SARI Guidelines (2019). Clinical Management of Severe Acute Respiratory Infection (SARI) when COVID-19 Disease is Suspected. Interim Guidance, 13 March 2020. Available at: https://apps.who.int/iris/handle/10665/331446

Soriano, J. B., Miravitlles, M., García-Rio, F., Muñoz, L., Sánchez, G., Sobradillo, V., et al. (2012). Spirometrically-defined Restrictive Ventilatory Defect: Population Variability and Individual Determinants. Prim. Care Respir. J. 21 (2), 187–193. doi:10.1104/pcri.2012.00027

Stanojevic, S., Graham, B. L., Cooper, B. G., Thompson, B. R., Carter, K. W., Francis, R. W., et al. (2017). Official ERS Technical Standards: Global Lung Function Initiative Reference Values for the Carbon Monoxide Transfer Factor for Caucasians. Eur. Respir. J. 50 (3), 1700010. doi:10.1183/13993003.00010-2017

Tognella, S., and Piccioni, P. (2021). Le prove di funzionalità respiratoria nell’era della pandemia da COVID-19. Position Paper AIPO – ITS. Available at: http://www.aiponet.it/news/speciale-covid-19/2471-le-prove-di-funzionalita-respiratoria-nell-era-della-pandemia-da-covid-19-position-paper-aipo-its.html

Torres-Castro, R., Vasconcellos-Castillo, L., Alcina-Navarro, L., Burgos, F., Cooper, B. G., et al. (2020). Pulmonary Function in Patients post-infection by COVID-19: A Systematic Review and Meta-Analysis. Pulmonology 27 (4), 328. doi:10.1016/j.pulmoe.2020.10.013

Venkataraman, T., and Frieman, M. B. (2017). The Role of Epidermal Growth Factor Receptor (EGFR) Signaling in SARS Coronavirus-Induced Pulmonary Fibrosis. Antiviral Res. 143, 142–150. doi:10.1016/j.antiviral.2017.03.022

Williams, N. (2017). The MRC Breathlessness Scale. Occup. Med. 67 (6), 496–497. doi:10.1093/occmed/kqx086

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Calabrese, Annunziata, Flora, Mariniello, Allocca, Palma, Coppola, Meoli, Pafundi and Fiorentino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.